51555-87-4
中文名称
D-吡喃半乳糖 Β-D-硫代吡喃半乳糖苷
英文名称
THIODIGALACTOSIDE
CAS
51555-87-4
分子式
C12H22O10S
分子量
358.36
MOL 文件
51555-87-4.mol
51555-87-4 结构式
基本信息
中文别名
硫代半乳糖苷N4苯甲酰基5'-O-DMT-5-甲基
D-吡喃半乳糖 Β-D-硫代吡喃半乳糖苷
(D-GALACTOPYRANOSYL)-B-D-THIOGALACTOPYRANOSIDE 硫代二半乳糖苷
英文别名
TDGTHIODIGALACTOSIDE
Galactosyl 1-thiogalactoside
D-Galactopyranosyl-b-D-thiogalactopyranoside
d-galactopyranosyl-β-d-thiogalactopyranoside
D-GALACTOPYRANOSYL BETA-D-THIOGALACTOPYRANOSIDE
D-Galactopyranosyl-β-D-thiogalactopyranoside ,98%
β-D-Galactopyranoside, β-D-galactopyranosyl 1-thio-
常见问题列表
生物活性
Thiodigalactoside (TDG) 是一种具有口服活性的，有效的半乳凝素 (GAL) 抑制剂，对于 GAL-1 和 GAL-3 的 Kd 值分别为 24 μM，49 μM。Thiodigalactoside 是一种不可代谢的二糖，具有抗炎和抗癌活性。Thiodigalactoside 可显着降低饮食诱发的肥胖大鼠的体重增加。靶点
Kd: 24 μM (GAL1) and 49 μM (GAL3)
体外研究
Thiodigalactoside (TDG; 250 and 500 μM) exhibits dose-dependent reduction of fat accumulation based on triglyceride (TG) content and Oil Red O (ORO) staining.
体内研究
Thiodigalactoside (TDG; 5 mg/kg; IP; once per week for 5 weeks) results in dramatic inhibition of HFD-induced body weight gain.
Thiodigalactoside (5 mg/kg; oral; daily or weekly for 5 weeks) gave less reduction in body weight gain compare with i.p..
| Animal Model: | Five-week-old Sprague-Dawley (SD) male rats |
| Dosage: | 5 mg/kg |
| Administration: | IP; once per week for 5 weeks |
| Result: | Resulted in dramatic inhibition of HFD-induced body weight gain by inhibiting adipogenesis and lipogensis as well as by increasing expression of the proteins associated with thermogenesis and energy expenditure. |